Rate of Differentiation Syndrome in Patients Based on Timing of Initial All-Trans Retinoic Acid Administration

Publication date: Available online 27 November 2019Source: Leukemia Research ReportsAuthor(s): Mary Nauffal, Lillian Werner, Jian Ni, Richard M. Stone, Daniel J. DeAngelo, Anne M. McDonnellAbstractAll-trans-retinoic acid (ATRA) is the standard of care for the management of acute promyelocytic leukemia. (APL), but can be associated with differentiation syndrome (DS). Over a seven-year period, we sought to determine the impact of ATRA initiation time on the development of DS. ATRA administration time had no impact on DS occurrence (p=0.13), APL risk (p=0.28) or regimen received (p=0.1). Patients with higher mean body mass index (BMI) were more likely to develop moderate or severe DS (p=0.02). Early treatment of APL is essential and maybe strongly considered in patients with elevated BMI.
Source: Leukemia Research Reports - Category: Hematology Source Type: research